Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Pleiotrophin

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101782

Synonyms

Historical Background

Pleiotrophin (PTN) is a secreted cell-signaling cytokine that acts as a growth factor associated with the extracellular matrix (ECM). It was discovered practically simultaneously by several laboratories nearly 25 years ago; thus, it initially received several names, as follows: HBGF-8 (heparin-binding growth factor (Milner et al. 1989); HB-GAM (heparin-binding growth-associated molecule) (Rauvala 1989; Merenmies and Rauvala 1990); HBNF (heparin-binding neurotrophic factor) (Kovesdi et al. 1990); OSF-1 (osteoblast-specific factor 1) (Tezuka et al. 1990), and HARP (heparin affinity regulatory peptide (Courty et al. 1991)). Some of these names are still in use in the literature, depending on the area of knowledge that the information generates; therefore, this can sometimes complicate the clear identification of the pleiad of actions and effects reported for PTN.

PTN shares high homology (>50%) with another peptide, denominated midkine (MK); both are highly conserved throughout evolution and are found in several species, ranging from Drosophila to humans (Kadomatsu and Muramatsu 2004). This conservation means that although both peptides could have many functions in common and could participate in similar functions, they also possess more particular, specific, and nonredundant functions. This is evident when both are simultaneously knocked out in mice: they display severe abnormality phenotypes. However, when independently knocked out, PTN−/− and MK−/− mice are far from being completely normal and exhibit moderate, but different, abnormalities (Muramatsu et al. 2006; Zou et al. 2006; Gramage and Herradon 2010; Himburg et al. 2012; Vicente-Rodriguez et al. 2013; Gonzalez-Castillo et al. 2016), which denotes that although both peptides could present overlapping or similar functions, they are also clearly involved in different roles.

As mentioned previously, PTN is highly conserved throughout its evolutive scale: its amino-acid sequence is nearly identical along different vertebrates (Fig. 1), its being interesting that there is even more similarity between PTN from rat or mouse with humans than with from pig or bovine (Fig. 2). It is also present in invertebrates, such as Drosophila, where it is involved in very similar functions (Reviewed in (Gonzalez-Castillo et al. 2014)), although with lesser percentage of conserved identical sequence.
Pleiotrophin, Fig. 1

Sequence alignment for pleiotrophin (PTN) from different species. Alignment was performed by using the Clustal Omega software program (Sievers et al. 2011)

Pleiotrophin, Fig. 2

Phylogenetic tree for pleiotrophin (PTN) from different species. Alignment for the phylogenetic tree was performed by utilizing the Clustal Omega software program (Sievers et al. 2011)

PTN is composed of 168 amino-acid residues; the first 32 correspond to the secretory signal sequence and these are cleaved prior to PTN secretion, while the remaining 136 residues constitute the mature secreted protein (Pantazaka 2012) (Fig. 3). PTN is a basic amino acid (24%) and cysteine-rich (8%) protein. Its ten cysteine residues are conserved in vertebrates and all form disulfide bonds (Hulmes et al. 1993) (Fig. 3). Although the calculated molecular weight (MW) of PTN is 15.3 kDa, it appears as an approximately 18-kDa band on gels, suggesting an anomalous migration due to the high percentage of basic amino-acid residues (Pantazaka 2012).
Pleiotrophin, Fig. 3

Sequence of human pleiotrophin (PTN). Localization of structural domains, cleavage sites, and sequence signatures (From information obtained in PROSITE (Sigrist et al. 2012))

Proteolytic cleavage of PTN has been described by plasmin (Polykratis et al. 2005) and MMP-2 (Dean et al. 2007) (Fig. 3) and has been related with different biological activities: tumor growth and angiogenesis, respectively. Cleavage by MMP-2 separates the two thrombospondin-1 repeats, yielding two fragments of approximately 6.6 and 6.4 KDa (Dean et al. 2007). Consequently, cleavage abrogates the mitogenic activity of PTN and significantly reduces its induced cell migration. Also, PTN binding with vascular endothelial growth factor (VEGF) prevents its cleavage by MMP-2 (Dean et al. 2007). Therefore, MMP-2 modulates PTN-induced cell proliferation and migration, and this action changes in the presence of VEGF.

On the other hand, cleavage by plasmin could theoretically generate up to five different small peptides of 16, 13, 10, 7, and 5.5 KDa (Polykratis et al. 2005). At least two of these, 16 and 13 KDa, have been detected by others (Bohlen and Kovesdi 1991; Hampton et al. 1992). Cleavage in the second site of the soluble form of PTN (K92–K93) yields two peptides, each containing only one β-sheet domain, which positively regulates angiogenesis in vitro, whereas PTN containing both β-sheet domains exert an inhibitory effect (Polykratis et al. 2005). Additionally, the presence of both domains is required when binding to VEGF165 (Heroult et al. 2004). Additionally, the third point-of-cleavage site removes a still unknown small portion of the C-terminal region, which is also implicated in its angiogenic activity (Bernard-Pierrot et al. 2001; Papadimitriou et al. 2001, 2009). This cleavage is necessary for the binding of PTN to anaplastic lymphoma kinase (ALK) receptor (Bernard-Pierrot et al. 2002; Ryan et al. 2016). This third cleavage site (question mark in Fig. 3) could correspond to the truncated form described by Lu et al. (2005), which is naturally processed by proteolytic cleavage and that has 12 residues less in the C-terminus, yielding a protein of an apparent MW of 15 KDa, named PTN15, to distinguish it from the complete PTN18 (Lu et al. 2005). Therefore, PTN is subject to regulatory proteolytic cleavage, at least by plasmin and MMP-2 and perhaps possibly by other proteases, which controls and organize their effects once secreted into the ECM.

Expression Profile of PTN

Since the first descriptions of the PTN expression profile (Nakamoto et al. 1992; Vanderwinden et al. 1992), increasing evidence has accumulated on the pleiotropic expression of the PTN peptide. During mammalian embryogenesis, PTN is highly expressed in the central nervous system (CNS) and the peripheral nervous system (PNS), as well as in organs undergoing branching morphogenesis, including the salivary glands, lung, and kidney, the digestive and skeletal systems, sense organs and facial processes, and limbs (Mitsiadis et al. 1995). PTN is mainly located in the basement membrane of the developing epithelium and in mesenchymal tissues undergoing remodeling, suggesting that it may play an important role in mesenchymal–epithelial interactions (Weng and Liu 2010). In the adult stage, PTN expression is mainly restricted to the CNS and to only few cell types therein (Reviewed in (Gonzalez-Castillo et al. 2014)). However, under pathological conditions, it can be overexpressed by quiescent hepatic stellate cells (HSC) during experimental fibrogenesis, comprising as a strong mitogenic signal for hepatocytes to limit damage to parenchymal cells in biliary-type liver fibrogenesis (Antoine et al. 2005). In addition, its expression in pathologic human intervertebral discs is associated with neovascularization of diseased or damaged disc tissue (Johnson et al. 2007), and it also is highly expressed in some types of cancers (see later).

The existence of at least two naturally occurring isoforms of PTN (Lu et al. 2005) and the recently demonstrated fact that each of these binds differentially to different receptor complexes (Ryan et al. 2016), as well as the multiple peptide that can be generated by proteolytic cleavage, mainly from plasmin and MMP-2 (previously described), imply the need for reinterpretation, or at least reconsideration, of practically all of the results reported to date for PTN functions and its effects, in order to correctly adjudicate each effect on each peptide fragment (for instance, PTN18, PTN15, or even others that are smaller), and/or on the respective receptor activated and signaling pathway triggered (see later). Additionally, the location and regulation of the expression of the enzymes that cleave PTN peptide acquire relevance in terms of regulating its actions.

PTN Signaling Through a Variety of Receptors or a Multireceptor Complex

As a growth factor, PTN signals are generally related with cell growth, proliferation, and differentiation, but PTN has also has been involved in other functions by acting through different receptors.

Mainly, PTN can bind and signal via receptor protein tyrosine phosphatase ζ (RPTPζ), EC = 3.1.3.48 (Maeda et al. 1996, 1999; Meng et al. 2000), which is a transmembrane chondroitin sulfate proteoglycan present in two isoforms (shorter and full length), which in turn also binds with various cell adhesion molecules (NrCAM, L1/Ng-CAM, contactin, N-CAM, and TAG1), growth factors (PTN, MK, and fibroblast growth factor 2 (FGF-2)), and ECM molecules (amphoterin, tenascin-C, and tenascin-R) (Reviewed in (Maeda et al. 2010)). The effects exerted through this receptor can be mainly attributed to PTN18, rather than to PTN15 (Ryan et al. 2016).

The intracellular phosphatase domains of receptor-type protein tyrosine phosphatase kappa (RPTP-κ) are proteolytically processed into isoforms that possess opposing effects on β-catenin activity. The RPTP-κ transmembrane P subunit interacts with and sequesters β-catenin at the cell membrane, where it can associate with E-cadherin and promote intercellular interactions. At high cell density, further processing of the P subunit yields a phosphatase intracellular portion (PIC) subunit, which chaperones β-catenin into the nucleus, where it can function to activate transcription (Sanchez-Morgan et al. 2011). PTPζ/β also dephosphorylates β-catenin, although PTPζ/β is inactivated when stimulated with PTN (Meng et al. 2000). This stimulation induces a morphological epithelial-to-mesenchymal transition in human GBM cells (Perez-Pinera et al. 2008). Thus, cleavage of the constitutively active RPTPζ/β would yield the same effect as PTN stimulation (Pariser et al. 2005). Therefore, PTN signaling can interact with Wnt signaling by altering β-catenin activity (Weng and Liu 2010).

According to Ryan et al. (2016), PTN15 is the truncated form that can act via anaplastic lymphoma kinase (ALK) receptor and exert reported actions (Stoica et al. 2001; Powers et al. 2002). Consequently, evidences suggesting that the action of PTN on ALK could occur through its previous interaction with RPTPζ (Perez-Pinera et al. 2007) must be reconsidered or at least reinterpreted.

Additionally, PTN can act through several other receptors as follows (Reviewed in (Gonzalez-Castillo et al. 2014)): (A) it promotes neurite outgrowth via the N-syndecan receptor (Raulo et al. 1994; Kinnunen et al. 1996) or via neuroglycan C (NGC) (Nakanishi et al. 2010); (B) it interacts with the integrin αυβ3 (alpha nu beta 3) receptor, a mechanosensitive cell membrane receptor, for cell adhesion (Mikelis et al. 2009), and (C) it interacts with the low-density lipoprotein (LDL) receptor-related protein (LRP) (Kadomatsu and Muramatsu 2004). However, in none of these cases has it been established to date which is the form (PTN18 or PTN15) that interacts with those receptors; therefore, their differential interaction or affinities to these different receptors has not yet been established, which adds another level of complexity to their physiological functioning.

It has been recently proposed that PTN signaling may function through a multireceptor complex (Xu et al. 2014), combining the previously mentioned receptors and, most probably, other adaptor proteins, which interact under certain circumstances inside particular cell membrane microdomains, probably also associated with lipids in raft configuration. The latter could explain the variety of functions in different tissues, in terms of the combinatorial analysis of the elements present at each time and place.

Then, PTN action on the previously mentioned receptors could, in turn, signal through different signal pathways (Fig. 4) (Reviewed in (Gonzalez-Castillo et al. 2014)). Increasing our knowledge of the intricate molecular mechanisms involved would clarify the receptor complexes and signaling pathways implicated, as well as advance the discovery of other molecules involved, which in turn would lead us to the full explanation of its variety of functions.
Pleiotrophin, Fig. 4

Pleiotrophin (PTN) action

PTN Classical Functions During Development

During development, PTN plays a role as a growth factor, signaling for cell growth, cell proliferation, and differentiation. PTN functions mainly during bone formation and chondrogenesis, as well as in organs undergoing branching morphogenesis, such as the kidney, lung, and in vascular tissue for angiogenesis (Fig. 4).

In Bone Formation and Chondrogenesis

PTN, also known as osteoblast-specific factor 1 (OSF-1), is highly expressed in fetal bone cartilage and is implicated in bone formation and remodeling (Tare et al. 2002). During the early stages of osteogenic differentiation, PTN is synthesized by osteocytes and localized at sites where new bones are formed (Imai et al. 1998; Tare et al. 2002). Therefore, based on its participation in angiogenesis as a heparin-binding angiogenic growth factor, a role in bone repair has been ascribed to PTN (Reviewed in (Lamprou et al. 2014)). Additionally, exogenous PTN, but not MK, promotes chondrogenesis in a micromass culture of chicken limb bud mesenchymal cells (Dreyfus et al. 1998). PTN promotes bone morphogenetic protein (BMP)-induced osteogenesis at a high concentration and has an opposite effect at a low concentration (Sato et al. 2002; Li et al. 2005).

Moreover, PTN can act as an inducer of hypertrophy during chondrogenic differentiation of human bone marrow stromal cells (hBMSC) (Bouderlique et al. 2014). Regarding therapy, PTN appears to mediate repair and protective processes in osteoarthritic cartilage and to be a promising factor for the treatment of osteoarthritis (Reviewed in (Mentlein 2007)).

In Kidney Development

In epithelial organogenesis, branching morphogenesis constitutes a central process, and PTN has been described as a key mesenchymally derived factor that regulates branching morphogenesis of the ureteric bud (Sakurai et al. 2001). Additionally, PTN expression is highly induced in human mesangial cells in vitro and triggers these to migrate (Martin et al. 2006).

In Lung Development

PTN has been involved, acting together with Wnt/β-catenin, for guiding the epithelial mesenchymal interactions during fibroblast and epithelial cell communication during fetal lung development (Weng et al. 2009; Weng and Liu 2010).

Function in Angiogenesis

PTN (−/−) mice displayed significantly decreased bone marrow (BM) hematopoietic stem cell (HSC) content and impaired hematopoietic regeneration following myelosuppression (Istvanffy et al. 2011). Conversely, mice lacking RPTPζ, which is inactivated by PTN, displayed significantly increased BM HSC content (Schinke et al. 2008). Therefore, PTN is a secreted component of the BM vascular niche that regulates HSC self-renewal and retention in vivo (Himburg et al. 2012). In addition, expression of endogenous PTN correlates with and appears to be involved in vivo in the angiogenesis of chicken embryo chorioallantoic membrane, and its action is mediated by nucleolin (Koutsioumpa et al. 2012). PTN is secreted by BM-derived endothelial cells and increased the survival of mice following radiation exposure and after myeloablative BM transplantation, mediating hematopoietic regeneration in a RAS-dependent manner (Himburg et al. 2014). Additionally, PTN acts as an angiogenesis “driver” by promoting the creation of a proangiogenic environment, migratory behavior in EC, and a proregenerative, alternative phenotype in macrophages (Palmieri et al. 2015). PTN is able to induce ex vivo angiogenesis during aging, constituting a promising therapy for inducing neovascularization in aged tissues (Besse et al. 2013).

As a Secretory Cytokine Involved in Cancer

Dissolution of cell–cell adhesive contacts and increased cell–ECM adhesion are hallmarks of the migratory and invasive phenotype of cancer cells. These changes are facilitated by growth factor binding to receptor protein tyrosine kinases (RTK). In normal cells, cell–cell adhesion molecules (CAM), including some receptor protein tyrosine phosphatases (RPTP), antagonize RTK signaling by promoting adhesion on migration. In cancer, RTK signaling is constitutive due to mutated or amplified RTK, which leads to growth factor independence or autonomy (Phillips-Mason et al. 2011).

PTN is highly expressed in different human tumors, in which it accelerates their growth and stimulates angiogenesis (Zhang et al. 2006; Perez-Pinera et al. 2008), including the following: (i) pancreatic (Yao et al. 2009, 2013), where it contributes to increased perineural invasion and poor prognosis; (ii) melanomas (Wu et al. 2005), where it is associated with its metastatic potential; (iii) in glioblastoma (Lu et al. 2005) and in astrocytomas (Peria et al. 2007), where is related with its histopathological grade; (iv) it is also a tumor growth factor for angiogenesis in some types of breast cancer (Fang et al. 1992; Wellstein et al. 1992; Czubayko et al. 1995; Chang et al. 2007); (v) for colorectal cancer, where could serve as a prognostic factor, because PTN promotes VEGF expression and cooperates with VEGF in promoting angiogenesis (Kong et al. 2012), and (vi) it is a stimulatory signal in prostate cancer (Hatziapostolou et al. 2006; Polytarchou et al. 2009; Orr et al. 2011).

Recently, Elahouel et al. (2015) demonstrated that PTN exert its action by interacting directly through its thrombospondin type-I repeat domains, with neuropilin 1 (NRP-1), which is a receptor for multiple growth factors that mediates cell motility and plays an important role in angiogenesis and tumor progression (Klagsbrun et al. 2002). Therefore, NRP-1/PTN interaction constitutes a novel mechanism for controlling the response of endothelial and tumoral cells to PTN and may explain, at least in part, how PTN contributes to tumor angiogenesis and cancer progression (Elahouel et al. 2015).

PTN as a Neuromodulatory Peptide with Multiple Neuronal Functions

In adult vertebrate CNS, PTN exerts post-developmental neurotrophic and protective effects and additionally has been involved in neurodegenerative disorders (Fig. 4). Consequently, PTN has been recently proposed as a neuromodulatory peptide in adult CNS (Gonzalez-Castillo et al. 2014).

Participates in Neurogenesis, Neural Migration, and Differentiation

PTN regulates neural stem-cell proliferation in vivo and in vitro. PTN knockout mice (PTN−/−) exhibit an increased proliferation rate of neuronal stem cells in adult mouse cerebral cortex, and exogenous PTN reduces neuronal stem-cell proliferation and promotes cell differentiation (Hienola et al. 2004). Additionally, neural migration in the rostral migratory stream is impaired in N-syndecan-null mice, one of the receptors of PTN (Hienola et al. 2006). Furthermore, PTN promotes the production of DAergic neurons from ES cell-derived, nestin-positive cells (Jung et al. 2004). Thus, PTN constitute a modulatory system that accounts for the balance between cell proliferation and differentiation in the vertebrate nervous system, which appears to be facilitated by the Brd2 antagonist mediated by PTN (Garcia-Gutierrez et al. 2014).

Contributes to Axonal and Neurite Outgrowth, Regeneration, and Neuron Survival

PTN serves as extracellular cues in axonal growth and guidance (Raulo et al. 2005), which induce neuritogenesis (Bao et al. 2005), as well as in neurite outgrowth (Kinnunen et al. 1996; Yanagisawa et al. 2010) and axonal outgrowth (Mitsiadis et al. 1995; Kadomatsu and Muramatsu 2004). In addition, it participates in dendritogenesis and synaptogenesis (Asai et al. 2009). Additionally, PTN constitutes a factor for peripheral nerve regeneration under pathological conditions (Blondet et al. 2006), which reverses the inhibition of neural regeneration elicited by chondroitin sulfate glycosaminoglycans (GAG) (Paveliev et al. 2016).

Is Involved in Hippocampal Memory and Learning

In the hippocampus, PTN expression is induced by long-term potentiation (LTP) (Lauri et al. 1996) and is involved in the regulation of synaptic plasticity (Lauri et al. 1998). Additionally, PTN inhibited hippocampal LTP induced by high-frequency stimulation (HFS) (del Olmo et al. 2009). Furthermore, PTN (−/−) exhibited enhanced hippocampal LTP (Amet et al. 2001), and transgenic mice overexpressing PTN have attenuated hippocampal LTP (Pavlov et al. 2002) by enhancing hippocampal GABAergic inhibition (Pavlov et al. 2006). Additionally, two knockout mice for receptors for PTN exhibited alterations in hippocampus-dependent memory. Syndecan-3-deficient mice exhibit enhanced LTP and impaired hippocampus-dependent memory (Kaksonen et al. 2002). Also, RPTPζ-deficient mice exhibit impairments in hippocampus-dependent contextual fear memory because of abnormal tyrosine phosphorylation of p190 RhoGAP, a GTPase-activating protein (GAP) for Rho GTPase (Tamura et al. 2006); therefore, PTN is able to modulate LTP by activity-dependent plasticity. Recently, it has been demonstrated that environmental enrichment increases PTN expression, which correlates with an improvement in cognition and brain functional markers in young senescence-accelerated prone mice (SAMP8) (Grinan-Ferre et al. 2016).

Modulates Nociceptive Transmission

PTN (−/−) mice exhibit a disruption of spinal nociceptive transmission in the control of pain processing (Gramage and Herradon 2010), potentiating analgesia caused by stimulation of α2-adrenoceptors (Vicente-Rodriguez et al. 2013), which is not altered in MK (−/−) mice (Gramage et al. 2012).

As a Secretory Cytokine Involved in Drug Addiction

PTN expression is increased in response to chronic drug consumption (Mailleux et al. 1994; Le Greves 2005) and is highly upregulated in different brain areas after administration of different drugs of abuse (Reviewed in (Herradon and Perez-Garcia 2014)). PTN deficiency confers vulnerability to developing neurodegenerative processes induced by drugs of abuse in humans. The genetic deletion of pleiotrophin (PTN−/−) shows enhanced amphetamine neurotoxicity (Gramage et al. 2010). Moreover, in mice with transgenic PTN overexpression, amphetamine caused an enhanced loss of striatal dopaminergic terminals in the striatum (Vicente-Rodriguez et al. 2016). PTN prevent the neurotoxic effects of amphetamine on nigrostriatal pathways, and endogenous PTN also limits amphetamine reward (Vicente-Rodriguez et al. 2016). In fact, there are several patents in existence for the use of PTN, as well as MK, in the treatment and diagnosis of neuropsychiatric disorders with a focus on neurotoxicity, neurodegeneration, and substance use disorders (Reviewed in (Alguacil and Herradon 2015)).

Participates in Neuroprotective Effect After Injury and Has Been Involved in Neurodegenerative Disorders

An increase in the expression of PTN in reactive astrocytes following hippocampal neuronal injury has been described (Takeda et al. 1995; Poulsen et al. 2000) and also in astrocytes after cryoinjury in mouse brain, providing a supportive environment for regenerating axons (Iseki et al. 2002). It has additionally been implicated in the denervated striatum of levodopa-treated rats (Ferrario et al. 2004), being involved in vitro in the survival of dopaminergic neurons (Marchionini et al. 2007) and as a potential neuroprotective agent for reconstruction of the DA nigrostriatal pathway (Gombash et al. 2014). Additionally, PTN promoted the proliferation of microglia and stimulated the secretion of neurotrophic factors by acting through the ERK1/ERK2 pathway after ischemia/reperfusion injury (Miao et al. 2012). Taken together, this evidence has led to the proposal, by several authors, that PTN possesses a neuroprotective effect.

In addition, PTN has been involved in neurodegenerative disorders. It has been reported as expressed in striatal interneurons (Taravini et al. 2005) and promoted functional recovery when PTN-treated donor cells were grafted into the striata of hemi-parkinsonian rats (Hida et al. 2007). In addition, PTN is upregulated in the degenerating substantia nigra of patients with Parkinson disease (PD) (Marchionini et al. 2007). Therefore, blocking RPTPζ/β has been proposed as a potential therapeutic strategy for the treatment of PD (Herradon et al. 2009), mainly because PTN overexpression provides trophic support to DAergic neurons in parkinsonian rats (Taravini et al. 2011).

PTN has been reported as highly expressed in amyloid-beta deposits in Alzheimer and Down brains (Wisniewski et al. 1996), although, to our knowledge, no one had reported similar results since. More recently, PTN has been involved in the development of neurodegenerative changes during aging (Grinan-Ferre et al. 2016).

Summary

PleioTrophiN (PTN) is a secreted cell-signaling cytokine that acts as a growth factor associated with the ExtraCellular Matrix (ECM), which is highly conserved throughout evolution. It is a relatively small peptide (136 residues and 18 KDa in its soluble form) that can additionally be fragmented by proteolytic cleavage in at least five different functional peptides. This implies the need for reinterpreting, or at least reconsidering, practically all of the results reported to date for PTN functions and effects. Also, it possesses several functional domains that can differentially interact with diverse receptors, and even with different receptor complexes. It is highly expressed during development in the Central (CNS) and Peripheral Nervous Systems (PNS), as well as in organs undergoing branching morphogenesis (lung, kidney, and vascular tissue), and during bone formation and chondrogenesis. It is generally located in the basement membrane of the developing epithelium and in mesenchymal tissues undergoing remodeling. Although during the adult stage its expression is confined mainly to CNS, its expression can be highly induced in response to damage in certain pathologies (such as fibrogenesis, neovascularization, and neuronal injury), and it is directly involved in carcinogenesis, where it accelerates tumor growth and stimulates angiogenesis. By its pleiad of actions such as soluble cytokines, its versatile and differential involvement in ECM cell – cell interactions, as well as their large number of functions in different tissues, PTN results in an extremely interesting modulatory peptide.

See Also

References

  1. Alguacil LF, Herradon G. Midkine and pleiotrophin in the treatment of neurodegenerative diseases and drug addiction. Recent Patents CNS Drug Discov. 2015;10:28–33.CrossRefGoogle Scholar
  2. Amet LE, Lauri SE, Hienola A, Croll SD, Lu Y, Levorse JM, et al. Enhanced hippocampal long-term potentiation in mice lacking heparin-binding growth-associated molecule. Mol Cell Neurosci. 2001;17:1014–24. doi:10.1006/mcne.2001.0998.PubMedCrossRefGoogle Scholar
  3. Antoine M, Tag CG, Wirz W, Borkham-Kamphorst E, Sawitza I, Gressner AM, et al. Upregulation of pleiotrophin expression in rat hepatic stellate cells by PDGF and hypoxia: implications for its role in experimental biliary liver fibrogenesis. Biochem Biophys Res Commun. 2005;337:1153–64. doi:10.1016/j.bbrc.2005.09.173.PubMedCrossRefGoogle Scholar
  4. Asai H, Yokoyama S, Morita S, Maeda N, Miyata S. Functional difference of receptor-type protein tyrosine phosphatase zeta/beta isoforms in neurogenesis of hippocampal neurons. Neuroscience. 2009;164:1020–30. doi:10.1016/j.neuroscience.2009.09.012.PubMedCrossRefGoogle Scholar
  5. Bao X, Mikami T, Yamada S, Faissner A, Muramatsu T, Sugahara K. Heparin-binding growth factor, pleiotrophin, mediates neuritogenic activity of embryonic pig brain-derived chondroitin sulfate/dermatan sulfate hybrid chains. J Biol Chem. 2005;280:9180–91. doi:10.1074/jbc.M413423200.PubMedCrossRefGoogle Scholar
  6. Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE. The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities. J Biol Chem. 2001;276:12228–34. doi:10.1074/jbc.M010913200.PubMedCrossRefGoogle Scholar
  7. Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D, et al. Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities. J Biol Chem. 2002;277:32071–7. doi:10.1074/jbc.M202747200.PubMedCrossRefGoogle Scholar
  8. Besse S, Comte R, Frechault S, Courty J, de Joel L, Delbe J. Pleiotrophin promotes capillary-like sprouting from senescent aortic rings. Cytokine. 2013;62:44–7. doi:10.1016/j.cyto.2013.02.002.PubMedCrossRefGoogle Scholar
  9. Blondet B, Carpentier G, Ferry A, Courty J. Exogenous pleiotrophin applied to lesioned nerve impairs muscle reinnervation. Neurochem Res. 2006;31:907–13. doi:10.1007/s11064-006-9095-x.PubMedCrossRefGoogle Scholar
  10. Bohlen P, Kovesdi I. HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function. Prog Growth Factor Res. 1991;3:143–57.PubMedCrossRefGoogle Scholar
  11. Bouderlique T, Henault E, Lebouvier A, Frescaline G, Bierling P, Rouard H, et al. Pleiotrophin commits human bone marrow mesenchymal stromal cells towards hypertrophy during chondrogenesis. PLoS ONE. 2014;9:e88287. doi:10.1371/journal.pone.0088287.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Chang Y, Zuka M, Perez-Pinera P, Astudillo A, Mortimer J, Berenson JR, et al. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A. 2007;104:10888–93. doi:10.1073/pnas.0704366104.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Courty J, Dauchel MC, Caruelle D, Perderiset M, Barritault D. Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem Biophys Res Commun. 1991;180:145–51.PubMedCrossRefGoogle Scholar
  14. Czubayko F, Schulte AM, Missner SC, Hsieh SS, Colley KJ, Wellstein A. Molecular and pharmacologic targeting of angiogenesis factors – the example of pleiotrophin. Breast Cancer Res Treat. 1995;36:157–68.PubMedCrossRefGoogle Scholar
  15. Dean RA, Butler GS, Hamma-Kourbali Y, Delbe J, Brigstock DR, Courty J, et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol. 2007;27:8454–65. doi:10.1128/MCB.00821-07.PubMedPubMedCentralCrossRefGoogle Scholar
  16. del Olmo N, Gramage E, Alguacil LF, Perez-Pinera P, Deuel TF, Herradon G. Pleiotrophin inhibits hippocampal long-term potentiation: a role of pleiotrophin in learning and memory. Growth Factors. 2009;27:189–94. doi:10.1080/08977190902906859.PubMedCrossRefGoogle Scholar
  17. Dreyfus J, Brunet-de Carvalho N, Duprez D, Raulais D, Vigny M. HB-GAM/pleiotrophin but not RIHB/midkine enhances chondrogenesis in micromass culture. Exp Cell Res. 1998;241:171–80. doi:10.1006/excr.1998.4040.PubMedCrossRefGoogle Scholar
  18. Elahouel R, Blanc C, Carpentier G, Frechault S, Cascone I, Destouches D, et al. Pleiotrophin exerts its migration and invasion effect through the neuropilin-1 pathway. Neoplasia. 2015;17:613–24. doi:10.1016/j.neo.2015.07.007.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem. 1992;267:25889–97.PubMedGoogle Scholar
  20. Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-Vozari R, et al. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem. 2004;90:1348–58. doi:10.1111/j.1471-4159.2004.02595.x.PubMedCrossRefGoogle Scholar
  21. Garcia-Gutierrez P, Juarez-Vicente F, Wolgemuth DJ, Garcia-Dominguez M. Pleiotrophin antagonizes Brd2 during neuronal differentiation. J Cell Sci. 2014;127:2554–64. doi:10.1242/jcs.147462.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, et al. Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways. Gene Ther. 2014;21:682–93. doi:10.1038/gt.2014.42.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Gonzalez-Castillo C, Ortuno-Sahagun D, Guzman-Brambila C, Pallas M, Rojas-Mayorquin AE. Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus. Front Cell Neurosci. 2014;8(443). doi:10.3389/fncel.2014.00443.Google Scholar
  24. Gonzalez-Castillo C, Ortuno-Sahagun D, Guzman-Brambila C, Marquez-Aguirre AL, Raisman-Vozari R, Pallas M, et al. The absence of pleiotrophin modulates gene expression in the hippocampus in vivo and in cerebellar granule cells in vitro. Mol Cell Neurosci. 2016;75:113–21. doi:10.1016/j.mcn.2016.07.004.PubMedCrossRefGoogle Scholar
  25. Gramage E, Herradon G. Genetic deletion of pleiotrophin leads to disruption of spinal nociceptive transmission: evidence for pleiotrophin modulation of morphine-induced analgesia. Eur J Pharmacol. 2010;647:97–102. doi:10.1016/j.ejphar.2010.08.029.PubMedCrossRefGoogle Scholar
  26. Gramage E, Rossi L, Granado N, Moratalla R, Herradon G. Genetic inactivation of pleiotrophin triggers amphetamine-induced cell loss in the substantia nigra and enhances amphetamine neurotoxicity in the striatum. Neuroscience. 2010;170:308–16. doi:10.1016/j.neuroscience.2010.06.078.PubMedCrossRefGoogle Scholar
  27. Gramage E, Martin YB, Herradon G. The heparin binding growth factors midkine and pleiotrophin regulate the antinociceptive effects of morphine through alpha(2)-adrenergic independent mechanisms. Pharmacol Biochem Behav. 2012;101:387–93. doi:10.1016/j.pbb.2012.02.001.PubMedCrossRefGoogle Scholar
  28. Grinan-Ferre C, Perez-Caceres D, Gutierrez-Zetina SM, Camins A, Palomera-Avalos V, Ortuno-Sahagun D, et al. Environmental enrichment improves behavior, cognition, and brain functional markers in young senescence-accelerated prone mice (SAMP8). Mol Neurobiol. 2016;53:2435–50. doi:10.1007/s12035-015-9210-6.PubMedCrossRefGoogle Scholar
  29. Hampton BS, Marshak DR, Burgess WH. Structural and functional characterization of full-length heparin-binding growth associated molecule. Mol Biol Cell. 1992;3:85–93.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem. 2006;281:32217–26. doi:10.1074/jbc.M607104200.PubMedCrossRefGoogle Scholar
  31. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene. 2004;23:1745–53. doi:10.1038/sj.onc.1206879.PubMedCrossRefGoogle Scholar
  32. Herradon G, Perez-Garcia C. Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives. Br J Pharmacol. 2014;171:837–48. doi:10.1111/bph.12312.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Herradon G, Ezquerra L, Gramage E, Alguacil LF. Targeting the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta signaling pathway to limit neurotoxicity induced by drug abuse. Mini-Rev Med Chem. 2009;9:440–7.PubMedCrossRefGoogle Scholar
  34. Hida H, Masuda T, Sato T, Kim TS, Misumi S, Nishino H. Pleiotrophin promotes functional recovery after neural transplantation in rats. NeuroReport. 2007;18:179–83. doi:10.1097/WNR.0b013e328011398e.PubMedCrossRefGoogle Scholar
  35. Hienola A, Pekkanen M, Raulo E, Vanttola P, Rauvala H. HB-GAM inhibits proliferation and enhances differentiation of neural stem cells. Mol Cell Neurosci. 2004;26:75–88. doi:10.1016/j.mcn.2004.01.018.PubMedCrossRefGoogle Scholar
  36. Hienola A, Tumova S, Kulesskiy E, Rauvala H. N-syndecan deficiency impairs neural migration in brain. J Cell Biol. 2006;174:569–80. doi:10.1083/jcb.200602043.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Himburg HA, Harris JR, Ito T, Daher P, Russell JL, Quarmyne M, et al. Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche. Cell Rep. 2012;2:964–75. doi:10.1016/j.celrep.2012.09.002.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Himburg HA, Yan X, Doan PL, Quarmyne M, Micewicz E, McBride W, et al. Pleiotrophin mediates hematopoietic regeneration via activation of RAS. J Clin Invest. 2014;124:4753–8. doi:10.1172/JCI76838.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Hulmes JD, Seddon AP, Decker MM, Bohlen P. Comparison of the disulfide bond arrangements of human recombinant and bovine brain heparin binding neurite-promoting factors. Biochem Biophys Res Commun. 1993;192:738–46. doi:10.1006/bbrc.1993.1476.PubMedCrossRefGoogle Scholar
  40. Imai S, Kaksonen M, Raulo E, Kinnunen T, Fages C, Meng X, et al. Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J Cell Biol. 1998;143:1113–28.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Iseki K, Hagino S, Mori T, Zhang Y, Yokoya S, Takaki H, et al. Increased syndecan expression by pleiotrophin and FGF receptor-expressing astrocytes in injured brain tissue. Glia. 2002;39:1–9. doi:10.1002/glia.10078.PubMedCrossRefGoogle Scholar
  42. Istvanffy R, Kroger M, Eckl C, Gitzelmann S, Vilne B, Bock F, et al. Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. Blood. 2011;118:2712–22. doi:10.1182/blood-2010-05-287235.PubMedCrossRefGoogle Scholar
  43. Johnson WE, Patterson AM, Eisenstein SM, Roberts S. The presence of pleiotrophin in the human intervertebral disc is associated with increased vascularization: an immunohistologic study. Spine. 2007;32:1295–302. doi:10.1097/BRS.0b013e31805b835d.PubMedCrossRefGoogle Scholar
  44. Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells. FASEB J. 2004;18:1237–9. doi:10.1096/fj.03-0927fje.PubMedGoogle Scholar
  45. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004;204:127–43. doi:10.1016/S0304-3835(03)00450-6.PubMedCrossRefGoogle Scholar
  46. Kaksonen M, Pavlov I, Voikar V, Lauri SE, Hienola A, Riekki R, et al. Syndecan-3-deficient mice exhibit enhanced LTP and impaired hippocampus-dependent memory. Mol Cell Neurosci. 2002;21:158–72.PubMedCrossRefGoogle Scholar
  47. Kinnunen T, Raulo E, Nolo R, Maccarana M, Lindahl U, Rauvala H. Neurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface. J Biol Chem. 1996;271:2243–8.PubMedCrossRefGoogle Scholar
  48. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol. 2002;515:33–48.PubMedCrossRefGoogle Scholar
  49. Kong Y, Bai PS, Nan KJ, Sun H, Chen NZ, Qi XG. Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int J Color Dis. 2012;27:287–98. doi:10.1007/s00384-011-1344-z.CrossRefGoogle Scholar
  50. Koutsioumpa M, Drosou G, Mikelis C, Theochari K, Vourtsis D, Katsoris P, et al. Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin. Vasc Cell. 2012;4:4. doi:10.1186/2045-824X-4-4.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Kovesdi I, Fairhurst JL, Kretschmer PJ, Bohlen P. Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins. Biochem Biophys Res Commun. 1990;172:850–4.PubMedCrossRefGoogle Scholar
  52. Lamprou M, Kaspiris A, Panagiotopoulos E, Giannoudis PV, Papadimitriou E. The role of pleiotrophin in bone repair. Injury. 2014;45:1816–23. doi:10.1016/j.injury.2014.10.013.PubMedCrossRefGoogle Scholar
  53. Lauri SE, Taira T, Kaila K, Rauvala H. Activity-induced enhancement of HB-GAM expression in rat hippocampal slices. NeuroReport. 1996;7:1670–4.PubMedCrossRefGoogle Scholar
  54. Lauri SE, Rauvala H, Kaila K, Taira T. Effect of heparin-binding growth-associated molecule (HB-GAM) on synaptic transmission and early LTP in rat hippocampal slices. Eur J Neurosci. 1998;10:188–94.PubMedCrossRefGoogle Scholar
  55. Le Greves P. Pleiotrophin gene transcription in the rat nucleus accumbens is stimulated by an acute dose of amphetamine. Brain Res Bull. 2005;65:529–32. doi:10.1016/j.brainresbull.2005.03.010.PubMedCrossRefGoogle Scholar
  56. Li G, Bunn JR, Mushipe MT, He Q, Chen X. Effects of pleiotrophin (PTN) over-expression on mouse long bone development, fracture healing and bone repair. Calcif Tissue Int. 2005;76:299–306. doi:10.1007/s00223-004-0145-6.PubMedCrossRefGoogle Scholar
  57. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, et al. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 2005;280:26953–64. doi:10.1074/jbc.M502614200.PubMedCrossRefGoogle Scholar
  58. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). J Biol Chem. 1996;271:21446–52.PubMedCrossRefGoogle Scholar
  59. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem. 1999;274:12474–9.PubMedCrossRefGoogle Scholar
  60. Maeda N, Fukazawa N, Ishii M. Chondroitin sulfate proteoglycans in neural development and plasticity. Front Biosci (Landmark Ed). 2010;15:626–44.CrossRefGoogle Scholar
  61. Mailleux P, Preud’homme X, Albala N, Vanderwinden JM, Vanderhaeghen JJ. delta-9-Tetrahydrocannabinol regulates gene expression of the growth factor pleiotrophin in the forebrain. Neurosci Lett. 1994;175:25–7.PubMedCrossRefGoogle Scholar
  62. Marchionini DM, Lehrmann E, Chu Y, He B, Sortwell CE, Becker KG, et al. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson’s disease. Brain Res. 2007;1147:77–88. doi:10.1016/j.brainres.2007.02.028.PubMedCrossRefGoogle Scholar
  63. Martin J, Bowen T, Steadman R. The pluripotent cytokine pleiotrophin is induced by wounding in human mesangial cells. Kidney Int. 2006;70:1616–22. doi:10.1038/sj.ki.5001800.PubMedCrossRefGoogle Scholar
  64. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, et al. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci U S A. 2000;97:2603–8. doi:10.1073/pnas.020487997.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Mentlein R. Targeting pleiotropin to treat osteoarthritis. Expert Opin Ther Targets. 2007;11:861–7. doi:10.1517/14728222.11.7.861.PubMedCrossRefGoogle Scholar
  66. Merenmies J, Rauvala H. Molecular cloning of the 18-kDa growth-associated protein of developing brain. J Biol Chem. 1990;265:16721–4.PubMedGoogle Scholar
  67. Miao J, Ding M, Zhang A, Xiao Z, Qi W, Luo N, et al. Pleiotrophin promotes microglia proliferation and secretion of neurotrophic factors by activating extracellular signal-regulated kinase 1/2 pathway. Neurosci Res. 2012;74:269–76. doi:10.1016/j.neures.2012.09.001.PubMedCrossRefGoogle Scholar
  68. Mikelis C, Sfaelou E, Koutsioumpa M, Kieffer N, Papadimitriou E. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J. 2009;23:1459–69. doi:10.1096/fj.08-117564.PubMedCrossRefGoogle Scholar
  69. Milner PG, Li YS, Hoffman RM, Kodner CM, Siegel NR, Deuel TF. A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem Biophys Res Commun. 1989;165:1096–103.PubMedCrossRefGoogle Scholar
  70. Mitsiadis TA, Salmivirta M, Muramatsu T, Muramatsu H, Rauvala H, Lehtonen E, et al. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development. 1995;121:37–51.PubMedGoogle Scholar
  71. Muramatsu H, Zou P, Kurosawa N, Ichihara-Tanaka K, Maruyama K, Inoh K, et al. Female infertility in mice deficient in midkine and pleiotrophin, which form a distinct family of growth factors. Genes Cells Devoted Mol Cell Mech. 2006;11:1405–17. doi:10.1111/j.1365-2443.2006.01028.x.CrossRefGoogle Scholar
  72. Nakamoto M, Matsubara S, Miyauchi T, Obama H, Ozawa M, Muramatsu T. A new family of heparin binding growth/differentiation factors: differential expression of the midkine (MK) and HB-GAM genes during mouse development. J Biochem. 1992;112:346–9.PubMedCrossRefGoogle Scholar
  73. Nakanishi K, Tokita Y, Aono S, Ida M, Matsui F, Higashi Y, et al. Neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, interacts with pleiotrophin, a heparin-binding growth factor. Neurochem Res. 2010;35:1131–7. doi:10.1007/s11064-010-0164-9.PubMedCrossRefGoogle Scholar
  74. Orr B, Vanpoucke G, Grace OC, Smith L, Anderson RA, Riddick AC, et al. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia. Prostate. 2011;71:305–17. doi:10.1002/pros.21244.PubMedCrossRefGoogle Scholar
  75. Palmieri D, Mura M, Mambrini S, Palombo D. Effects of Pleiotrophin on endothelial and inflammatory cells: pro-angiogenic and anti-inflammatory properties and potential role for vascular bio-prosthesis endothelialization. Adv Med Sci. 2015;60:287–93. doi:10.1016/j.advms.2015.05.003.PubMedCrossRefGoogle Scholar
  76. Pantazaka EPE. PTN (pleiotrophin). Atlas Genet Cytogenet Oncol Haematol. 2012;16:821–37. doi:10.4267/2042/48231.Google Scholar
  77. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P. HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides. Biochem Biophys Res Commun. 2001;282:306–13. doi:10.1006/bbrc.2001.4574.PubMedCrossRefGoogle Scholar
  78. Papadimitriou E, Mikelis C, Lampropoulou E, Koutsioumpa M, Theochari K, Tsirmoula S, et al. Roles of pleiotrophin in tumor growth and angiogenesis. Eur Cytokine Netw. 2009;20:180–90. doi:10.1684/ecn.2009.0172.PubMedGoogle Scholar
  79. Pariser H, Herradon G, Ezquerra L, Perez-Pinera P, Deuel TF. Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C. Proc Natl Acad Sci U S A. 2005;102:12407–12. doi:10.1073/pnas.0505901102.PubMedPubMedCentralCrossRefGoogle Scholar
  80. Paveliev M, Fenrich KK, Kislin M, Kuja-Panula J, Kulesskiy E, Varjosalo M, et al. HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix. Sci Rep. 2016;6:33916. doi:10.1038/srep33916.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Pavlov I, Voikar V, Kaksonen M, Lauri SE, Hienola A, Taira T, et al. Role of heparin-binding growth-associated molecule (HB-GAM) in hippocampal LTP and spatial learning revealed by studies on overexpressing and knockout mice. Mol Cell Neurosci. 2002;20:330–42.PubMedCrossRefGoogle Scholar
  82. Pavlov I, Rauvala H, Taira T. Enhanced hippocampal GABAergic inhibition in mice overexpressing heparin-binding growth-associated molecule. Neuroscience. 2006;139:505–11. doi:10.1016/j.neuroscience.2005.11.070.PubMedCrossRefPubMedCentralGoogle Scholar
  83. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem. 2007;282:28683–90. doi:10.1074/jbc.M704505200.PubMedCrossRefPubMedCentralGoogle Scholar
  84. Perez-Pinera P, Berenson JR, Deuel TF. Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis. Curr Opin Hematol. 2008;15:210–4. doi:10.1097/MOH.0b013e3282fdc69e.PubMedCrossRefPubMedCentralGoogle Scholar
  85. Peria FM, Neder L, Marie SK, Rosemberg S, Oba-Shinjo SM, Colli BO, et al. Pleiotrophin expression in astrocytic and oligodendroglial tumors and it’s correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J Neuro-Oncol. 2007;84:255–61. doi:10.1007/s11060-007-9379-2.CrossRefGoogle Scholar
  86. Phillips-Mason PJ, Craig SE, Brady-Kalnay SM. Should I stay or should I go? Shedding of RPTPs in cancer cells switches signals from stabilizing cell-cell adhesion to driving cell migration. Cell Adhes Migr. 2011;5:298–305.CrossRefGoogle Scholar
  87. Polykratis A, Katsoris P, Courty J, Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem. 2005;280:22454–61. doi:10.1074/jbc.M414407200.PubMedCrossRefPubMedCentralGoogle Scholar
  88. Polytarchou C, Hatziapostolou M, Poimenidi E, Mikelis C, Papadopoulou A, Parthymou A, et al. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta. Int J Cancer. 2009;124:1785–93. doi:10.1002/ijc.24084.PubMedCrossRefPubMedCentralGoogle Scholar
  89. Poulsen FR, Lagord C, Courty J, Pedersen EB, Barritault D, Finsen B. Increased synthesis of heparin affin regulatory peptide in the perforant path lesioned mouse hippocampal formation. Exp Brain Res. 2000;135:319–30.PubMedCrossRefGoogle Scholar
  90. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem. 2002;277:14153–8. doi:10.1074/jbc.M112354200.PubMedCrossRefPubMedCentralGoogle Scholar
  91. Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J Biol Chem. 1994;269:12999–3004.PubMedPubMedCentralGoogle Scholar
  92. Raulo E, Tumova S, Pavlov I, Pekkanen M, Hienola A, Klankki E, et al. The two thrombospondin type I repeat domains of the heparin-binding growth-associated molecule bind to heparin/heparan sulfate and regulate neurite extension and plasticity in hippocampal neurons. J Biol Chem. 2005;280:41576–83. doi:10.1074/jbc.M506457200.PubMedCrossRefPubMedCentralGoogle Scholar
  93. Rauvala H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J. 1989;8:2933–41.PubMedPubMedCentralGoogle Scholar
  94. Ryan E, Shen D, Wang X. Structural studies reveal an important role for the pleiotrophin C-terminus in mediating interactions with chondroitin sulfate. FEBS J. 2016;283:1488–503. doi:10.1111/febs.13686.PubMedCrossRefPubMedCentralGoogle Scholar
  95. Sakurai H, Bush KT, Nigam SK. Identification of pleiotrophin as a mesenchymal factor involved in ureteric bud branching morphogenesis. Development. 2001;128:3283–93.PubMedPubMedCentralGoogle Scholar
  96. Sanchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE. The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits beta-catenin transcriptional activity in lung cancer cells. Mol Cell Biol. 2011;31:3286–97. doi:10.1128/MCB.01426-10.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Sato Y, Takita H, Ohata N, Tamura M, Kuboki Y. Pleiotrophin regulates bone morphogenetic protein (BMP)-induced ectopic osteogenesis. J Biochem. 2002;131:877–86.PubMedCrossRefGoogle Scholar
  98. Schinke T, Gebauer M, Schilling AF, Lamprianou S, Priemel M, Mueldner C, et al. The protein tyrosine phosphatase Rptpzeta is expressed in differentiated osteoblasts and affects bone formation in mice. Bone. 2008;42:524–34. doi:10.1016/j.bone.2007.11.009.PubMedCrossRefPubMedCentralGoogle Scholar
  99. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7:539. doi:10.1038/msb.2011.75.Google Scholar
  100. Sigrist CJ, de Castro E, Cerutti L, Cuche BA, Hulo N, Bridge A, Bougueleret L, Xenarios I. New and continuing developments at PROSITE. Nucleic Acids Res. 2013;41:D344–7. doi:10.1093/nar/gks1067. Epub 2012 Nov 17.Google Scholar
  101. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001;276:16772–9. doi:10.1074/jbc.M010660200.PubMedCrossRefPubMedCentralGoogle Scholar
  102. Takeda A, Onodera H, Sugimoto A, Itoyama Y, Kogure K, Rauvala H, et al. Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury. Neuroscience. 1995;68:57–64.PubMedCrossRefGoogle Scholar
  103. Tamura H, Fukada M, Fujikawa A, Noda M. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. Neurosci Lett. 2006;399:33–8. doi:10.1016/j.neulet.2006.01.045.PubMedCrossRefPubMedCentralGoogle Scholar
  104. Taravini IR, Ferrario JE, Delbe J, Ginestet L, Debeir T, Courty J, et al. Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons. Brain Res. 2005;1066:196–200. doi:10.1016/j.brainres.2005.10.055.PubMedCrossRefPubMedCentralGoogle Scholar
  105. Taravini IR, Chertoff M, Cafferata EG, Courty J, Murer MG, Pitossi FJ, et al. Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Mol Neurodegener. 2011;6:40. doi:10.1186/1750-1326-6-40.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Tare RS, Oreffo RO, Clarke NM, Roach HI. Pleiotrophin/Osteoblast-stimulating factor 1: dissecting its diverse functions in bone formation. J Bone Miner Res. 2002;17:2009–20. doi:10.1359/jbmr.2002.17.11.2009.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Tezuka K, Takeshita S, Hakeda Y, Kumegawa M, Kikuno R, Hashimoto-Gotoh T. Isolation of mouse and human cDNA clones encoding a protein expressed specifically in osteoblasts and brain tissues. Biochem Biophys Res Commun. 1990;173:246–51.PubMedCrossRefGoogle Scholar
  108. Vanderwinden JM, Mailleux P, Schiffmann SN, Vanderhaeghen JJ. Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat Embryol. 1992;186:387–406.PubMedCrossRefGoogle Scholar
  109. Vicente-Rodriguez M, Perez-Garcia C, Gramage E, Herradon G. Genetic inactivation of pleiotrophin but not midkine potentiates clonidine-induced alpha-2 adrenergic-mediated analgesia. Pharmacol Biochem Behav. 2013;110:185–91. doi:10.1016/j.pbb.2013.07.013.PubMedCrossRefPubMedCentralGoogle Scholar
  110. Vicente-Rodriguez M, Rojo Gonzalez L, Gramage E, Fernandez-Calle R, Chen Y, Perez-Garcia C, et al. Pleiotrophin overexpression regulates amphetamine-induced reward and striatal dopaminergic denervation without changing the expression of dopamine D1 and D2 receptors: Implications for neuroinflammation. Eur Neuropsychopharmacol. 2016. doi:10.1016/j.euroneuro.2016.09.002.PubMedPubMedCentralGoogle Scholar
  111. Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, et al. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem. 1992;267:2582–7.PubMedPubMedCentralGoogle Scholar
  112. Weng T, Liu L. The role of pleiotrophin and beta-catenin in fetal lung development. Respir Res. 2010;11(80). doi:10.1186/1465-9921-11-80.Google Scholar
  113. Weng T, Gao L, Bhaskaran M, Guo Y, Gou D, Narayanaperumal J, et al. Pleiotrophin regulates lung epithelial cell proliferation and differentiation during fetal lung development via beta-catenin and Dlk1. J Biol Chem. 2009;284:28021–32. doi:10.1074/jbc.M109.052530.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Wisniewski T, Lalowski M, Baumann M, Rauvala H, Raulo E, Nolo R, et al. HB-GAM is a cytokine present in Alzheimer’s and Down’s syndrome lesions. NeuroReport. 1996;7:667–71.PubMedCrossRefGoogle Scholar
  115. Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol. 2005;32:125–30. doi:10.1111/j.0303-6987.2005.00282.x.PubMedCrossRefPubMedCentralGoogle Scholar
  116. Xu C, Zhu S, Wu M, Han W, Yu Y. Functional receptors and intracellular signal pathways of midkine (MK) and pleiotrophin (PTN). Biol Pharm Bull. 2014;37:511–20.PubMedCrossRefGoogle Scholar
  117. Yanagisawa H, Komuta Y, Kawano H, Toyoda M, Sango K. Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP)-43 mRNA through the ALK/GSK3beta/beta-catenin signaling in developing mouse neurons. Neurosci Res. 2010;66:111–6. doi:10.1016/j.neures.2009.10.002.PubMedCrossRefPubMedCentralGoogle Scholar
  118. Yao J, Ma Q, Wang L, Zhang M. Pleiotrophin expression in human pancreatic cancer and its correlation with clinicopathological features, perineural invasion, and prognosis. Dig Dis Sci. 2009;54:895–901. doi:10.1007/s10620-008-0433-5.PubMedCrossRefPubMedCentralGoogle Scholar
  119. Yao J, XF H, Feng XS, Gao SG. Pleiotrophin promotes perineural invasion in pancreatic cancer. World J Gastroenterol. 2013;19:6555–8. doi:10.3748/wjg.v19.i39.6555.PubMedPubMedCentralCrossRefGoogle Scholar
  120. Zhang N, Zhong R, Perez-Pinera P, Herradon G, Ezquerra L, Wang ZY, et al. Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. Biochem Biophys Res Commun. 2006;343:653–8. doi:10.1016/j.bbrc.2006.03.006.PubMedCrossRefPubMedCentralGoogle Scholar
  121. Zou P, Muramatsu H, Sone M, Hayashi H, Nakashima T, Muramatsu T. Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response. Lab Invest J Tech Method Pathol. 2006;86:645–53. doi:10.1038/labinvest.3700428.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Departamento de Ciencias Ambientales, Instituto de Neurociencias, CUCBAUniversidad de GuadalajaraGuadalajaraMexico
  2. 2.Departamento de Biología Molecular y Genómica, CUCS, Instituto de Investigación en Ciencias Biomédicas (IICB)Universidad de GuadalajaraGuadalajaraMexico